Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer
Background: Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients. Methods: Refractory CRPC patients were enrolled onto this 3+3 dose escalation designed study. Imatinib pharmacoki...
Gespeichert in:
| Veröffentlicht in: | British journal of cancer 2012-08, Vol.107 (4), p.592-597 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 597 |
|---|---|
| container_issue | 4 |
| container_start_page | 592 |
| container_title | British journal of cancer |
| container_volume | 107 |
| creator | Nabhan, C Villines, D Valdez, T V Tolzien, K Lestingi, T M Bitran, J D Christner, S M Egorin, M J Beumer, J H |
| description | Background:
Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients.
Methods:
Refractory CRPC patients were enrolled onto this 3+3 dose escalation designed study. Imatinib pharmacokinetics (PK) were determined on day 15, 4 h post dose with a validated LC–MS assay.
Results:
Seventeen patients were enrolled; 10 evaluable (6 at 400 mg S qd with 300 mg IM qd (DL0) and 4 at 400 mg S bid with 300 mg IM qd (DL1)); inevaluable patients received |
| doi_str_mv | 10.1038/bjc.2012.312 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3419960</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2730443981</sourcerecordid><originalsourceid>FETCH-LOGICAL-c480t-b742151ea478e5b487bacd973215f34d5d45664ae33da3279a85a0ae81abab733</originalsourceid><addsrcrecordid>eNptkU2LFDEQhoMo7rh68ywBERTsMR_d090XQRZdFxb0oOemkq6eydCTjElmpH-Vf9FqZlxX8JSPenjrrXoZey7FUgrdvDNbu1RCqqWW6gFbyEqrQjaqfsgWQoi6EK0SF-xJSlt6tqKpH7MLpRpBXLVgv75uICG_4Skf-ok7f8SU3Rqy82ueN8gTDJgnDr7nA0Jyxo2O3mHgNuyM8zPndjPvDN9hmkbIyF9fj4hHtG_4T5c3PIVIMjPhPN8TjD6nUyniEMHmECduIeVIxeCLiMmlDD7zfQx0IUkL3mJ8yh4NMCZ8dj4v2fdPH79dfS5uv1zfXH24LWzZiFyYulSykghl3WBlyqY2YPu21vQ76LKv-rJarUpArXvQqm6hqUAANhIMmFrrS_b-pLs_mB32lgxHGLt9pFnj1AVw3b8V7zbdOhw7Xcq2XQkSeHkWiOHHgZbabcMhevLcUWyqqiqlV0S9PVGWxky0i7sOUsxc01G83RxvR_ES_uK-qzv4T54EvDoDkCyMtFpvXfrLraixbOfxihOXqOTXGO-7-0_j3zMEwdg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1032555236</pqid></control><display><type>article</type><title>Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer</title><source>MEDLINE</source><source>Springer Nature - Connect here FIRST to enable access</source><source>PubMed Central</source><source>EZB Electronic Journals Library</source><source>Springer Online Journals - JUSTICE</source><creator>Nabhan, C ; Villines, D ; Valdez, T V ; Tolzien, K ; Lestingi, T M ; Bitran, J D ; Christner, S M ; Egorin, M J ; Beumer, J H</creator><creatorcontrib>Nabhan, C ; Villines, D ; Valdez, T V ; Tolzien, K ; Lestingi, T M ; Bitran, J D ; Christner, S M ; Egorin, M J ; Beumer, J H</creatorcontrib><description>Background:
Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients.
Methods:
Refractory CRPC patients were enrolled onto this 3+3 dose escalation designed study. Imatinib pharmacokinetics (PK) were determined on day 15, 4 h post dose with a validated LC–MS assay.
Results:
Seventeen patients were enrolled; 10 evaluable (6 at 400 mg S qd with 300 mg IM qd (DL0) and 4 at 400 mg S bid with 300 mg IM qd (DL1)); inevaluable patients received <1 cycle. The median age was 73 (57–89); median prostatic serum antigen was 284 ng ml
−1
(11.7–9027). Median number of prior non-hormonal therapies was 3 (1–12). Dose-limiting toxicities were diarrhoea and hand-foot syndrome. Maximum tolerated dose was 400 mg S and 300 mg IM both daily. No biochemical responses were observed. Two patients had stable disease by RECIST. Median time to progression was 2 months (1–5). Median OS was 6 months (1–30+) with 3/17 patients (17%) alive at 21 months median follow-up. Ten patients had PK data suggesting that S reduced IM clearance by 55%, resulting in 77% increased exposure (
P
=0.005; compared with historical data).
Conclusion:
This is the first report showing that S+IM can be administered in CRPC at a dose of 400 mg S and 300 mg IM, daily.</description><identifier>ISSN: 0007-0920</identifier><identifier>EISSN: 1532-1827</identifier><identifier>DOI: 10.1038/bjc.2012.312</identifier><identifier>PMID: 22805325</identifier><identifier>CODEN: BJCAAI</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>631/92/436/108 ; 692/699/67/589/466 ; 692/700/565/1436/1437 ; Adult ; Aged ; Aged, 80 and over ; Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Benzamides ; Benzenesulfonates - administration & dosage ; Biological and medical sciences ; Biomedical and Life Sciences ; Biomedicine ; Bisphosphonates ; Cancer Research ; Cancer therapies ; Castration ; Chemotherapy ; Clinical Study ; Cytotoxicity ; Drug Administration Schedule ; Drug dosages ; Drug Resistance ; Epidemiology ; Hematology ; Humans ; Imatinib Mesylate ; Male ; Maximum Tolerated Dose ; Medical research ; Medical sciences ; Medicine ; Metastasis ; Middle Aged ; Molecular Medicine ; Nephrology. Urinary tract diseases ; Niacinamide - analogs & derivatives ; Oncology ; Phenylurea Compounds ; Piperazines - administration & dosage ; Piperazines - pharmacokinetics ; Prostate cancer ; Prostatic Neoplasms - drug therapy ; Pyridines - administration & dosage ; Pyrimidines - administration & dosage ; Pyrimidines - pharmacokinetics ; Retreatment ; Treatment Failure ; Tumors ; Tumors of the urinary system ; Urinary tract. Prostate gland</subject><ispartof>British journal of cancer, 2012-08, Vol.107 (4), p.592-597</ispartof><rights>The Author(s) 2012</rights><rights>2015 INIST-CNRS</rights><rights>Copyright Nature Publishing Group Aug 7, 2012</rights><rights>Copyright © 2012 Cancer Research UK 2012 Cancer Research UK</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c480t-b742151ea478e5b487bacd973215f34d5d45664ae33da3279a85a0ae81abab733</citedby><cites>FETCH-LOGICAL-c480t-b742151ea478e5b487bacd973215f34d5d45664ae33da3279a85a0ae81abab733</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419960/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419960/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,41464,42533,51294,53766,53768</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=26255193$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22805325$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nabhan, C</creatorcontrib><creatorcontrib>Villines, D</creatorcontrib><creatorcontrib>Valdez, T V</creatorcontrib><creatorcontrib>Tolzien, K</creatorcontrib><creatorcontrib>Lestingi, T M</creatorcontrib><creatorcontrib>Bitran, J D</creatorcontrib><creatorcontrib>Christner, S M</creatorcontrib><creatorcontrib>Egorin, M J</creatorcontrib><creatorcontrib>Beumer, J H</creatorcontrib><title>Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer</title><title>British journal of cancer</title><addtitle>Br J Cancer</addtitle><addtitle>Br J Cancer</addtitle><description>Background:
Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients.
Methods:
Refractory CRPC patients were enrolled onto this 3+3 dose escalation designed study. Imatinib pharmacokinetics (PK) were determined on day 15, 4 h post dose with a validated LC–MS assay.
Results:
Seventeen patients were enrolled; 10 evaluable (6 at 400 mg S qd with 300 mg IM qd (DL0) and 4 at 400 mg S bid with 300 mg IM qd (DL1)); inevaluable patients received <1 cycle. The median age was 73 (57–89); median prostatic serum antigen was 284 ng ml
−1
(11.7–9027). Median number of prior non-hormonal therapies was 3 (1–12). Dose-limiting toxicities were diarrhoea and hand-foot syndrome. Maximum tolerated dose was 400 mg S and 300 mg IM both daily. No biochemical responses were observed. Two patients had stable disease by RECIST. Median time to progression was 2 months (1–5). Median OS was 6 months (1–30+) with 3/17 patients (17%) alive at 21 months median follow-up. Ten patients had PK data suggesting that S reduced IM clearance by 55%, resulting in 77% increased exposure (
P
=0.005; compared with historical data).
Conclusion:
This is the first report showing that S+IM can be administered in CRPC at a dose of 400 mg S and 300 mg IM, daily.</description><subject>631/92/436/108</subject><subject>692/699/67/589/466</subject><subject>692/700/565/1436/1437</subject><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Benzamides</subject><subject>Benzenesulfonates - administration & dosage</subject><subject>Biological and medical sciences</subject><subject>Biomedical and Life Sciences</subject><subject>Biomedicine</subject><subject>Bisphosphonates</subject><subject>Cancer Research</subject><subject>Cancer therapies</subject><subject>Castration</subject><subject>Chemotherapy</subject><subject>Clinical Study</subject><subject>Cytotoxicity</subject><subject>Drug Administration Schedule</subject><subject>Drug dosages</subject><subject>Drug Resistance</subject><subject>Epidemiology</subject><subject>Hematology</subject><subject>Humans</subject><subject>Imatinib Mesylate</subject><subject>Male</subject><subject>Maximum Tolerated Dose</subject><subject>Medical research</subject><subject>Medical sciences</subject><subject>Medicine</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Molecular Medicine</subject><subject>Nephrology. Urinary tract diseases</subject><subject>Niacinamide - analogs & derivatives</subject><subject>Oncology</subject><subject>Phenylurea Compounds</subject><subject>Piperazines - administration & dosage</subject><subject>Piperazines - pharmacokinetics</subject><subject>Prostate cancer</subject><subject>Prostatic Neoplasms - drug therapy</subject><subject>Pyridines - administration & dosage</subject><subject>Pyrimidines - administration & dosage</subject><subject>Pyrimidines - pharmacokinetics</subject><subject>Retreatment</subject><subject>Treatment Failure</subject><subject>Tumors</subject><subject>Tumors of the urinary system</subject><subject>Urinary tract. Prostate gland</subject><issn>0007-0920</issn><issn>1532-1827</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptkU2LFDEQhoMo7rh68ywBERTsMR_d090XQRZdFxb0oOemkq6eydCTjElmpH-Vf9FqZlxX8JSPenjrrXoZey7FUgrdvDNbu1RCqqWW6gFbyEqrQjaqfsgWQoi6EK0SF-xJSlt6tqKpH7MLpRpBXLVgv75uICG_4Skf-ok7f8SU3Rqy82ueN8gTDJgnDr7nA0Jyxo2O3mHgNuyM8zPndjPvDN9hmkbIyF9fj4hHtG_4T5c3PIVIMjPhPN8TjD6nUyniEMHmECduIeVIxeCLiMmlDD7zfQx0IUkL3mJ8yh4NMCZ8dj4v2fdPH79dfS5uv1zfXH24LWzZiFyYulSykghl3WBlyqY2YPu21vQ76LKv-rJarUpArXvQqm6hqUAANhIMmFrrS_b-pLs_mB32lgxHGLt9pFnj1AVw3b8V7zbdOhw7Xcq2XQkSeHkWiOHHgZbabcMhevLcUWyqqiqlV0S9PVGWxky0i7sOUsxc01G83RxvR_ES_uK-qzv4T54EvDoDkCyMtFpvXfrLraixbOfxihOXqOTXGO-7-0_j3zMEwdg</recordid><startdate>20120807</startdate><enddate>20120807</enddate><creator>Nabhan, C</creator><creator>Villines, D</creator><creator>Valdez, T V</creator><creator>Tolzien, K</creator><creator>Lestingi, T M</creator><creator>Bitran, J D</creator><creator>Christner, S M</creator><creator>Egorin, M J</creator><creator>Beumer, J H</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>C6C</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7TO</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AN0</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M7P</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>5PM</scope></search><sort><creationdate>20120807</creationdate><title>Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer</title><author>Nabhan, C ; Villines, D ; Valdez, T V ; Tolzien, K ; Lestingi, T M ; Bitran, J D ; Christner, S M ; Egorin, M J ; Beumer, J H</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c480t-b742151ea478e5b487bacd973215f34d5d45664ae33da3279a85a0ae81abab733</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>631/92/436/108</topic><topic>692/699/67/589/466</topic><topic>692/700/565/1436/1437</topic><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Benzamides</topic><topic>Benzenesulfonates - administration & dosage</topic><topic>Biological and medical sciences</topic><topic>Biomedical and Life Sciences</topic><topic>Biomedicine</topic><topic>Bisphosphonates</topic><topic>Cancer Research</topic><topic>Cancer therapies</topic><topic>Castration</topic><topic>Chemotherapy</topic><topic>Clinical Study</topic><topic>Cytotoxicity</topic><topic>Drug Administration Schedule</topic><topic>Drug dosages</topic><topic>Drug Resistance</topic><topic>Epidemiology</topic><topic>Hematology</topic><topic>Humans</topic><topic>Imatinib Mesylate</topic><topic>Male</topic><topic>Maximum Tolerated Dose</topic><topic>Medical research</topic><topic>Medical sciences</topic><topic>Medicine</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Molecular Medicine</topic><topic>Nephrology. Urinary tract diseases</topic><topic>Niacinamide - analogs & derivatives</topic><topic>Oncology</topic><topic>Phenylurea Compounds</topic><topic>Piperazines - administration & dosage</topic><topic>Piperazines - pharmacokinetics</topic><topic>Prostate cancer</topic><topic>Prostatic Neoplasms - drug therapy</topic><topic>Pyridines - administration & dosage</topic><topic>Pyrimidines - administration & dosage</topic><topic>Pyrimidines - pharmacokinetics</topic><topic>Retreatment</topic><topic>Treatment Failure</topic><topic>Tumors</topic><topic>Tumors of the urinary system</topic><topic>Urinary tract. Prostate gland</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nabhan, C</creatorcontrib><creatorcontrib>Villines, D</creatorcontrib><creatorcontrib>Valdez, T V</creatorcontrib><creatorcontrib>Tolzien, K</creatorcontrib><creatorcontrib>Lestingi, T M</creatorcontrib><creatorcontrib>Bitran, J D</creatorcontrib><creatorcontrib>Christner, S M</creatorcontrib><creatorcontrib>Egorin, M J</creatorcontrib><creatorcontrib>Beumer, J H</creatorcontrib><collection>Springer Open Access</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>ProQuest Nursing & Allied Health Database</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>ProQuest Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central UK/Ireland</collection><collection>British Nursing Database</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Biological Sciences</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>PML(ProQuest Medical Library)</collection><collection>Biological Science Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nabhan, C</au><au>Villines, D</au><au>Valdez, T V</au><au>Tolzien, K</au><au>Lestingi, T M</au><au>Bitran, J D</au><au>Christner, S M</au><au>Egorin, M J</au><au>Beumer, J H</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer</atitle><jtitle>British journal of cancer</jtitle><stitle>Br J Cancer</stitle><addtitle>Br J Cancer</addtitle><date>2012-08-07</date><risdate>2012</risdate><volume>107</volume><issue>4</issue><spage>592</spage><epage>597</epage><pages>592-597</pages><issn>0007-0920</issn><eissn>1532-1827</eissn><coden>BJCAAI</coden><abstract>Background:
Determining the maximum tolerated dose (MTD) and the dose-limiting toxicity (DLT) of sorafenib (S) plus imatinib (IM) in castration-resistant prostate cancer (CRPC) patients.
Methods:
Refractory CRPC patients were enrolled onto this 3+3 dose escalation designed study. Imatinib pharmacokinetics (PK) were determined on day 15, 4 h post dose with a validated LC–MS assay.
Results:
Seventeen patients were enrolled; 10 evaluable (6 at 400 mg S qd with 300 mg IM qd (DL0) and 4 at 400 mg S bid with 300 mg IM qd (DL1)); inevaluable patients received <1 cycle. The median age was 73 (57–89); median prostatic serum antigen was 284 ng ml
−1
(11.7–9027). Median number of prior non-hormonal therapies was 3 (1–12). Dose-limiting toxicities were diarrhoea and hand-foot syndrome. Maximum tolerated dose was 400 mg S and 300 mg IM both daily. No biochemical responses were observed. Two patients had stable disease by RECIST. Median time to progression was 2 months (1–5). Median OS was 6 months (1–30+) with 3/17 patients (17%) alive at 21 months median follow-up. Ten patients had PK data suggesting that S reduced IM clearance by 55%, resulting in 77% increased exposure (
P
=0.005; compared with historical data).
Conclusion:
This is the first report showing that S+IM can be administered in CRPC at a dose of 400 mg S and 300 mg IM, daily.</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>22805325</pmid><doi>10.1038/bjc.2012.312</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-0920 |
| ispartof | British journal of cancer, 2012-08, Vol.107 (4), p.592-597 |
| issn | 0007-0920 1532-1827 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_3419960 |
| source | MEDLINE; Springer Nature - Connect here FIRST to enable access; PubMed Central; EZB Electronic Journals Library; Springer Online Journals - JUSTICE |
| subjects | 631/92/436/108 692/699/67/589/466 692/700/565/1436/1437 Adult Aged Aged, 80 and over Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - therapeutic use Benzamides Benzenesulfonates - administration & dosage Biological and medical sciences Biomedical and Life Sciences Biomedicine Bisphosphonates Cancer Research Cancer therapies Castration Chemotherapy Clinical Study Cytotoxicity Drug Administration Schedule Drug dosages Drug Resistance Epidemiology Hematology Humans Imatinib Mesylate Male Maximum Tolerated Dose Medical research Medical sciences Medicine Metastasis Middle Aged Molecular Medicine Nephrology. Urinary tract diseases Niacinamide - analogs & derivatives Oncology Phenylurea Compounds Piperazines - administration & dosage Piperazines - pharmacokinetics Prostate cancer Prostatic Neoplasms - drug therapy Pyridines - administration & dosage Pyrimidines - administration & dosage Pyrimidines - pharmacokinetics Retreatment Treatment Failure Tumors Tumors of the urinary system Urinary tract. Prostate gland |
| title | Phase I study investigating the safety and feasibility of combining imatinib mesylate (Gleevec) with sorafenib in patients with refractory castration-resistant prostate cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T17%3A30%3A26IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Phase%20I%20study%20investigating%20the%20safety%20and%20feasibility%20of%20combining%20imatinib%20mesylate%20(Gleevec)%20with%20sorafenib%20in%20patients%20with%20refractory%20castration-resistant%20prostate%20cancer&rft.jtitle=British%20journal%20of%20cancer&rft.au=Nabhan,%20C&rft.date=2012-08-07&rft.volume=107&rft.issue=4&rft.spage=592&rft.epage=597&rft.pages=592-597&rft.issn=0007-0920&rft.eissn=1532-1827&rft.coden=BJCAAI&rft_id=info:doi/10.1038/bjc.2012.312&rft_dat=%3Cproquest_pubme%3E2730443981%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1032555236&rft_id=info:pmid/22805325&rfr_iscdi=true |